Fingerprint
Dive into the research topics of 'First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1
Amit Mahipal, Samuel Ejadi, Sacha Gnjatic, Seunghee Kim-Schulze, Hailing Lu, Jan H. ter Meulen, Richard Kenney, Kunle Odunsi
Research output: Contribution to journal › Article › peer-review
8
Scopus
citations